Skip to main content

Revvity Diagnostics revenue

  • RVTY · NYSE
  • Instruments
  • Health Care Equipment
  • S&P 500
$154.39−1.67%Close 13 Nov 2026 · Market value $16.71B

Diagnostics revenue at Revvity came to $349.3M for the quarter to 4 Oct 2026, down 1.9% from a year earlier.

As Revvity reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 10 Nov 2026.

By quarter

$324.4MMar 2025$354.4MJun 2025$356.1MSep 2025$390.1MDec 2025$349.3MApr 2026$371.0MJul 2026$349.3MOct 2026
Revvity Diagnostics revenue, every reported period
Period endingDiagnostics revenueChange on a yearFiled
4 Oct 2026$349.3Mdown 1.9%10 Nov 2026
5 Jul 2026$371.0Mup 4.7%11 Aug 2026
5 Apr 2026$349.3Mup 7.7%12 May 2026
28 Dec 2025$390.1M—24 Feb 2026
28 Sep 2025$356.1M—4 Nov 2025
29 Jun 2025$354.4M—5 Aug 2025
30 Mar 2025$324.4M—6 May 2025

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Revvity: Reconciliati on of financial organic revenue growth from continuing operations (change on a year) · Product revenue · Service revenue · Life Sciences revenue · United States revenue · China revenue · Americas revenue · Europe revenue · Germany revenue · Asia revenue · United Kingdom revenue · financial statements

Every KPI and segment of RVTY, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.